LLY — ELI LILLY & CO
Health Care · Drug Manufacturers
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying LLY?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 5 tracked investors who changed their LLY position last quarter, 5 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime). 3 congressional purchases, 3 sales disclosed in the last 6 months.
- +5 tracked investors added or increased positions last quarter (Paul Tudor Jones, Steve Cohen, George Soros, …)
- +7 tracked investors reported holding LLY at their latest filing
- +Macro Health is 52/100 in a Squeeze regime — historically acceptable for Health Caresource
- +3 congressional purchases disclosed in the last 6 months
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.
About ELI LILLY & CO (LLY)
ELI LILLY & CO (LLY) appears in the most recent 13F filings of 7 tracked institutional investors. ELI LILLY & CO is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $3.3B. Across recent filings, tracked investors recorded 9 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in LLY
How many top investors track LLY
Several tracked investors have exposure.
LLY Ownership Composition
How ELI LILLY & CO is held across tracked investor types, based on reported 13F positions.
- Other96.0%
- Hedge Funds3.7%
- Growth Funds0.3%
Tracked investors reporting LLY
- Ken GriffinMar 31, 2026Citadel AdvisorsShares3.5MValue$3.3B% Portfolio0.53%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares907.4KValue$834.6M% Portfolio0.35%
- Paul Tudor JonesMar 31, 2026Tudor Investment CorpShares157.3KValue$144.7M% Portfolio0.27%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares157.7KValue$145M% Portfolio0.19%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares70.8KValue$65.1M% Portfolio0.29%
- George SorosMar 31, 2026Soros Fund ManagementShares22.2KValue$20.4M% Portfolio0.22%
- Cathie WoodMar 31, 2026ARK Investment ManagementShares12.7KValue$11.7M% Portfolio0.09%
Recent activity
- $215.4MFeb 17, 2026
- $144.7MMay 15, 2026
- New$197.6MFeb 17, 2026
- New$145MMay 15, 2026
- New$24MFeb 13, 2026
- New$20.4MMay 15, 2026
- New$65.1MMay 15, 2026
- New$11.7MMay 12, 2026
- Sold$0(-100.00%)Feb 13, 2026
- New$8KNov 13, 2025
Frequently asked questions
- How many institutional investors hold LLY?
- 7 tracked institutional investors disclosed a position in LLY (ELI LILLY & CO) in their most recent 13F filing.
- Who is the largest institutional holder of LLY?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in LLY, valued at $3.3B.
- Did institutional ownership of LLY increase or decrease?
- Across recent 13F filings, tracked investors recorded 9 new positions, 0 increased, 0 reduced, and 1 fully exited LLY.
- What sector is LLY in?
- ELI LILLY & CO is classified in the Health Care GICS sector, Drug Manufacturers industry.
- Where does this LLY ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.